Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Pfizer's Staph Vaccine: Can Narrow Trial Population Support Broader Claim?

Executive Summary

US FDA advisory committee will weigh in on clinical development plan for SA4Ag, an S. aureus vaccine for prophylactic use, including whether safety and efficacy data from an ongoing, Phase II trial in spinal surgery patients are generalizable to other elective orthopedic surgical populations.

You may also be interested in...

Pfizer Persists: Big Opportunities And Challenges In Vaccines

The big pharma has two vaccines that have progressed to late-stage development, one for Clostridium difficile infection and the other for Staph aureus. Both represent big commercial opportunities, but bringing a new vaccine to market is a slow process.

Pfizer STRIVEs For Staph Vaccine Broad Claim, But Future Development May Hinge On US FDA

If Pfizer doesn't get regulatory clarity that Phase IIb/III STRIVE study data could support broad indication in elective orthopedic surgeries, company says it would have to reassess resources needed to continue current development program, with study termination a possible outcome.

Pfizer Staph Vaccine Trial May Support Claim For Some, But Not All, Orthopedic Surgeries

US FDA advisory committee members say if SA4Ag is efficacious in ongoing trial of spinal surgery patients, efficacy data could support a broader claim encompassing limited number of other orthopedic procedures with similar pathophysiology and infection risk, such as hip and knee replacement surgeries.

Related Content


Related Companies




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts